Fig. 1: Patient disposition.

CONSORT flow diagram of patient disposition and eligibility in the analysis of acquired resistance mutations in the FLAURA trial *Plasma provided at baseline and at disease progression or treatment discontinuation. EGFR epidermal growth factor receptor, p.o. orally, qd once daily, TKI tyrosine kinase inhibitor.